grant
Brain Tumor SPORE Grant
Organization UNIVERSITY OF CALIFORNIA, SAN FRANCISCOLocation SAN FRANCISCO, UNITED STATESPosted 20 Sept 2002Deadline 31 Aug 2028
NIHUS FederalResearch GrantFY20252-ketoglutarate2-oxoglutarateAccelerationAchievementAchievement AttainmentAddressAdoptedAdoptive TransferAgeAntigensAutologousBiologicalBiological MarkersBiometricsBiometryBiostatisticsBloodBlood Reticuloendothelial SystemBody TissuesBrainBrain CancerBrain NeoplasiaBrain NeoplasmsBrain Nervous SystemBrain TumorsCAR T cell therapyCAR T cellsCAR T therapyCAR modified T cellsCAR-TCAR-TsCNS Nervous SystemCNS TumorCNS neoplasmCell BodyCellsCellular immunotherapyCentral Nervous SystemCentral Nervous System NeoplasmsCentral Nervous System TumorsClinicClinicalComprehensive Cancer CenterDNA MethylationDeath RateDevelopmentDexamethasoneDiagnosisDiagnosticEarly treatmentEncephalonEvaluationExhibitsFacultyFamilyFundingGenesGenetic EngineeringGenetic Engineering BiotechnologyGenetic Engineering Molecular BiologyGlial Cell TumorsGlial NeoplasmGlial TumorGlioblastomaGliomaGlutamatesGrade IV Astrocytic NeoplasmGrade IV Astrocytic TumorGrade IV AstrocytomaGrantHeterogeneityHeterograftHeterologous TransplantationHomingHumanIV InfusionImageImmuneImmune mediated therapyImmunesImmunologically Directed TherapyImmunomodulationImmunotherapyIncidenceIndividualIntravenous infusion proceduresInvestigatorsIsocitrate DehydrogenaseL-GlutamateLab FindingsLaboratory FindingMR ImagingMR TomographyMRIMRIsMagnetic Resonance ImagingMalignant Tumor of the BrainMalignant neoplasm of brainMeasuresMedical Imaging, Magnetic Resonance / Nuclear Magnetic ResonanceMetabolic MarkerMethodsModalityModelingModern ManMyeloid-derived suppressor cellsNMR ImagingNMR TomographyNeuraxisNeuroglial NeoplasmNeuroglial TumorNeurosurgeonNuclear Magnetic Resonance ImagingPathologyPatient CarePatient Care DeliveryPatientsPersonsPhase I StudyPhenotypePre-Clinical ModelPreclinical ModelsPreclinical dataProductionPyruvateR-Series Research ProjectsR01 MechanismR01 ProgramRadiographyReceptor ProteinRecombinant DNA TechnologyResearchResearch GrantsResearch PersonnelResearch Project GrantsResearch ProjectsResearchersResectedRoentgenographyRoleSafetySamplingScientistStratificationSystemT cell based immune therapyT cell based therapeuticsT cell based therapyT cell directed therapiesT cell immune therapyT cell immunotherapyT cell targeted therapeuticsT cell therapyT cell treatmentT cell-based immunotherapyT cell-based treatmentT cells for CART cellular immunotherapyT cellular therapyT lymphocyte based immunotherapyT lymphocyte based therapyT lymphocyte therapeuticT lymphocyte treatmentT-CellsT-LymphocyteT-cell therapeuticsT-cell transfer therapyTechniquesTestingTherapeuticTissuesToxic effectToxicitiesTranslatingTranslational ResearchTranslational ScienceTumor BurdenTumor LoadWorkXenograftXenograft procedureXenotransplantationZeugmatographyadoptive T cell transferadoptive T lymphocyte transferadoptive T-cell therapyagesalpha ketoglutaratebio-markersbiologicbiologic markerbiomarkerblood-based biomarkerblood-based markercare for patientscare of patientscareercaring for patientscell-based immunotherapychimeric antigen T cell receptorchimeric antigen receptorchimeric antigen receptor (CAR) T cell therapychimeric antigen receptor (CAR) T cellschimeric antigen receptor Tchimeric antigen receptor T cell therapychimeric antigen receptor T cellschimeric antigen receptor T therapychimeric antigen receptor fusion protein T-cellschimeric antigen receptor modified T cellsdetermine efficacydevelopmentalearly biomarkersearly detection biomarkersearly detection markersearly therapyefficacy analysisefficacy assessmentefficacy determinationefficacy evaluationefficacy examinationevaluate efficacyexamine efficacyexhaustionfirst in manfirst-in-humangenetically engineeredglial-derived tumorglioblastoma multiformeglutamatergicimagingimaging approachimaging based approachimaging biomarkerimaging markerimaging probeimaging-based biological markerimaging-based biomarkerimaging-based markerimmune cell therapyimmune modulationimmune regulationimmune therapeutic approachimmune therapeutic interventionsimmune therapeutic regimensimmune therapeutic strategyimmune therapyimmune-based therapiesimmune-based treatmentsimmuno therapyimmunogenimmunologic reactivity controlimmunomodulatoryimmunoregulationimmunoregulatoryimmunosuppressive myeloid cellsimprovedinnovateinnovationinnovativeintravenous infusionirradiation responsemembermethylation biomarkermethylation markermortality ratemortality ratiomutantmyeloid suppressor cellsmyeloid-derived suppressive cellsneuro-oncologyneuro-surgeonneuroglia neoplasmneuroglia tumorneurooncologynew therapeutic approachnew therapeutic interventionnew therapeutic strategiesnew therapy approachesnew treatment approachnew treatment strategynon-invasive imagingnoninvasive imagingnotchnotch proteinnotch receptorsnovelnovel therapeutic approachnovel therapeutic interventionnovel therapeutic strategiesnovel therapy approachperipheral bloodphase 1 studyphase 1 trialphase I trialpre-clinical studypreclinical findingspreclinical informationpreclinical studyprognosis modelprognostic modelprognostic toolprogramsprospectiveradiation responseradiological imagingreceptorresponseresponse biomarkerresponse markersresponse to radiationresponse to therapyresponse to treatmentsocial rolespongioblastoma multiformesuppressive myeloid cellstherapeutic T-cell platformtherapeutic responsetherapy responsethymus derived lymphocytetooltranslation researchtranslational investigationtreatment responsetreatment responsivenesstumortumor of the central nervous systemtumors in the braintumors in the central nervous systemxeno-transplantxeno-transplantationα-ketoglutarateα-oxoglutarateαKG
Description preview
Project Summary/Abstract
This SPORE renewal application represents the efforts of interdisciplinary teams of investigators from the Neuro-
Oncology Program of the UCSF Helen Diller Family Comprehensive Cancer Center (HDFCCC) to build on our
accomplishments to continue to translate our findings to improve care for patients with brain cancer. We…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click